SARcode Corporation
SARcode is a private, San Francisco based company focused on the development of small molecule LFA-1 inhibitors to treat inflammatory diseases. In December, 2006 SARcode secured $25 million in a financing co-led by Alta Partners and Clarus Ventures.
News Release
March 30, 2009
SARcode Announces Results of Phase 1 Trial of SAR 1118 Ophthalmic Solution in Healthy Adult Subjects
March 9, 2009
Sunesis Pharmaceuticals Announces the Sale of its LFA-1 Inhibitor Program to SARcode Corporation
December 11, 2008
SARcode Announces Completion of Phase 1 Clinical Trial of SAR 1118
Ophthalmic Solution
September 5, 2008
SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
SARcode Corporation
343 Sansome St.
Suite 505
San Francisco, CA 94104-5622
SARcode@sarcode.com